Aradigm Corp fka ARDMQ

[thee trader]

Capitalizing on Unmet Needs in the Specialty
Pharmaceutical Market

Aradigm has redefined its business strategy to independently forge a leading position in the specialty pharmaceutical market. With its highly targeted strategic development efforts, clinical expertise and the strength of a well accomplished leadership force, the company is well positioned to capitalize on niche opportunities for new and improved products used in the treatment of severe respiratory disease. The company will achieve this mission by building on its core expertise and focusing on the following strategic efforts:

• Continued development of proprietary respiratory disease therapies;

• Pursue regulatory pathways that reduce the time, costs and risks associated with product development;

• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing;

• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists and sub-specialists in the United States;

• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise.

http://www.aradigm.com/about_bus_over.html